epoxyketone tetrapeptide
Carfilzomib clinical trials
Answer
Carfilzomib has 308 registered trials: 96 running, 119 completed, 43 stopped early. 91 posted results.
Trial registerClinicalTrials.gov and EU CTIS, read 2026-10-03
| Trial | Title | Status | Phase | Registered | Results |
|---|---|---|---|---|---|
| NCT04925193 Trial register | Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma | running, but no longer enrolling | - | 2021-06-14 | Posted |
| NCT07715903 Trial register | Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy | not yet recruiting participants | - | 2026-07-21 | - |
| 2024-515279-37-00 Trial register | A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell T | Not stated | 3 | - | - |
| NCT06948084 Trial register | Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or D | currently recruiting participants | - | 2025-04-29 | - |
| NCT01559935 Trial register | Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma | completed | - | 2012-03-21 | Posted |
| NCT06055075 Trial register | A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple M | terminated before completion | - | 2023-09-26 | Posted |
| NCT07222761 Trial register | A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participant | currently recruiting participants | - | 2025-10-30 | - |
| NCT07391657 Trial register | A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refra | currently recruiting participants | - | 2026-02-06 | - |
| NCT07605416 Trial register | Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial | currently recruiting participants | - | 2026-05-26 | - |
| 2023-503444-13-00 Trial register | A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Particip | Not stated | 3 | - | - |
| NCT04973605 Trial register | A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, an | currently recruiting participants | - | 2021-07-22 | - |
| NCT05050097 Trial register | A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma | running, but no longer enrolling | - | 2021-09-20 | - |
| NCT05438043 Trial register | A Study of Daratumumab | running, but no longer enrolling | - | 2022-06-29 | - |
| NCT05552976 Trial register | A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relaps | running, but no longer enrolling | - | 2022-09-23 | - |
| 2024-515783-31-00 Trial register | Elotuzumab (E) in Combination with Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) versus KRd prior to and following Autologous Stem Cell Transplant in Newl | Not stated | 3 | - | - |
| NCT05789303 Trial register | Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma | currently recruiting participants | - | 2023-03-29 | - |
| NCT03909412 Trial register | Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma | currently recruiting participants | - | 2019-04-10 | - |
| NCT04096066 Trial register | A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant | running, but no longer enrolling | - | 2019-09-19 | - |
| NCT04661137 Trial register | A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma | currently recruiting participants | - | 2020-12-10 | - |
| NCT04933539 Trial register | Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma | running, but no longer enrolling | - | 2021-06-21 | - |
| 2023-507751-30-00 Trial register | A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 as Monotherapy, in Combination With Dexamethasone, Dex | Not stated | 1/2 | - | - |
| 2026-525913-30-00 Trial register | A parallel group, Phase 3, randomized, open-label, 2-arm study to demonstrate the superiority of belumosudil versus best available therapy (BAT) in participants | Not stated | 3 | - | - |
| NCT04883242 Trial register | Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma | running, but no longer enrolling | - | 2021-05-12 | - |
| NCT03004287 Trial register | 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy | running, but no longer enrolling | - | 2016-12-28 | - |
| NCT04756401 Trial register | Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma | running, but no longer enrolling | - | 2021-02-16 | Posted |
| NCT06615479 Trial register | A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Mul | currently recruiting participants | - | 2024-09-26 | - |
| NCT01279694 Trial register | Trial of Carfilzomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma (CARMYSAP) | completed | - | 2011-01-19 | - |
| NCT07555938 Trial register | Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma | currently recruiting participants | - | 2026-04-29 | - |
| 2024-516905-22-00 Trial register | Induction therapy with bortezomib, melphalan and prednisone (VMP) followed by lenalidomide and dexamethasone (Rd) vs. carfilzomib, lenalidomide and dexamethason | Not stated | 3 | - | - |
| 2022-500861-29-00 Trial register | A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKd) Versus Carf | Not stated | 3 | - | - |
| 2024-510799-19-00 Trial register | A Phase 1b/2a Multicenter, Open-label, Dose Escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Effi | Not stated | 1/2 | - | - |
| 2023-508870-27-00 Trial register | A randomized, Phase 2, open label study evaluating subcutaneous administration of isatuximab in combination with carfilzomib and dexamethasone in adult particip | Not stated | 2 | - | - |
| NCT07479979 Trial register | Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma | currently recruiting participants | - | 2026-03-18 | - |
| 2024-511791-32-00 Trial register | A Clinical Phase II, multicenter, Open-label study evaluating iNduction, consolidation and maintenance treatment with Isatuximab (SAR650984), Carfilzomib, LEnal | Not stated | 2 | - | - |
| NCT06158841 Trial register | Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multipl | running, but no longer enrolling | - | 2023-12-06 | - |
| NCT01959698 Trial register | Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma | running, but no longer enrolling | - | 2013-10-10 | Posted |
| 2023-506668-15-00 Trial register | A Phase 3, Multicenter, Randomized, Open Label Study of Etentamig Compared With Standard Available Therapy in Subjects With Relapsed or Refractory Multiple Myel | Not stated | 3 | - | - |
| NCT07227311 Trial register | A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myelo | currently recruiting participants | - | 2025-11-12 | - |
| NCT01297764 Trial register | A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma | running, but no longer enrolling | - | 2011-02-17 | - |
| NCT06152575 Trial register | MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatment | currently recruiting participants | - | 2023-11-30 | - |
| NCT07772024 Trial register | Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma | currently recruiting participants | - | 2026-08-13 | - |
| NCT05651932 Trial register | A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma | currently recruiting participants | - | 2022-12-15 | - |
| NCT06627751 Trial register | Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease | currently recruiting participants | - | 2024-10-04 | - |
| NCT04113018 Trial register | Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma | running, but no longer enrolling | - | 2019-10-02 | Posted |
| NCT05675449 Trial register | A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma | running, but no longer enrolling | - | 2023-01-09 | - |
| NCT06622005 Trial register | SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | currently recruiting participants | - | 2024-10-01 | - |
| NCT07463807 Trial register | Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone | currently recruiting participants | - | 2026-03-11 | - |
| NCT06918990 Trial register | Treatment of Antibody-Mediated Rejection (ABMR) With CarBel | currently recruiting participants | - | 2025-04-09 | - |
| NCT05669989 Trial register | International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab | enrolling by invitation only | - | 2023-01-03 | - |
| NCT04458831 Trial register | A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) | completed | - | 2020-07-07 | - |
| NCT06413498 Trial register | A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma | running, but no longer enrolling | - | 2024-05-14 | - |
| NCT07728188 Trial register | A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relaps | not yet recruiting participants | - | 2026-07-27 | - |
| 2025-524028-23-00 Trial register | A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Cevostamab in Combination with Pomalidomide and Dexamethasone Versu | Not stated | 3 | - | - |
| NCT06892522 Trial register | A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Anti | currently recruiting participants | - | 2025-03-24 | - |
| NCT03798678 Trial register | CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma | running, but no longer enrolling | - | 2019-01-10 | - |
| NCT07709884 Trial register | A Single-center, Prospective, Single-arm Clinical Study Exploring the Treatment of Newly Diagnosed Multiple Myeloma Patients With t(11;14) Suitable for Transpla | not yet recruiting participants | - | 2026-07-17 | - |
| NCT04483739 Trial register | Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL) | running, but no longer enrolling | - | 2020-07-23 | - |
| NCT02343042 Trial register | Selinexor and Backbone Treatments of Multiple Myeloma Patients | currently recruiting participants | - | 2015-01-21 | - |
| NCT04822337 Trial register | Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma | running, but no longer enrolling | - | 2021-03-30 | - |
| NCT05199311 Trial register | Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma | suspended | - | 2022-01-20 | - |
| NCT05137054 Trial register | A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is R | currently recruiting participants | - | 2021-11-30 | - |
| NCT07689006 Trial register | Real-World Clinical Outcomes in Relapsed/Refractory Multiple Myeloma Treated With Pomalidomide Regimens | completed | - | 2026-06-30 | - |
| 2023-505659-27-00 Trial register | A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination with Carfilzomib and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myelo | Not stated | 2 | - | - |
| NCT04850599 Trial register | Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma | running, but no longer enrolling | - | 2021-04-20 | - |
| NCT05041933 Trial register | Secure Outsourcing of Carfilzomib in the Treatment of Multiple Myeloma to the Hospital at Home Setting | completed | - | 2021-09-13 | - |
| NCT03651128 Trial register | Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) | completed | - | 2018-08-29 | - |
| NCT03556332 Trial register | A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Tra | running, but no longer enrolling | - | 2018-06-14 | - |
| NCT07652879 Trial register | KCD (Carfilzomib/Cyclophosphamide/Dexamethasone) Regimen for the Treatment of Newly Diagnosed POEMS Syndrome | currently recruiting participants | - | 2026-06-17 | - |
| NCT02332850 Trial register | Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma | completed | - | 2015-01-07 | - |
| 2023-510215-18-00 Trial register | RElapse from Mrd Negativity As iNdication for Treatment | Not stated | 2/3 | - | - |
| 2025-523117-28-00 Trial register | A Phase 2, multicenter, open label, non-randomized study to evaluate the efficacy and safety of extended dosing of belantamab mafodotin in different combination | Not stated | 2 | - | - |
| NCT05620238 Trial register | Home Treatment With Carfilzomib in Patients With Multiple Myeloma | completed | - | 2022-11-17 | - |
| NCT04176718 Trial register | Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM | running, but no longer enrolling | - | 2019-11-25 | - |
| NCT04430894 Trial register | KRDI in Transplant-Eligible MM | running, but no longer enrolling | - | 2020-06-12 | Posted |
| NCT05434689 Trial register | COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide | running, but no longer enrolling | - | 2022-06-28 | - |
| NCT03290950 Trial register | A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma | running, but no longer enrolling | - | 2017-09-25 | Posted |
| 2024-513422-38-00 Trial register | Phase III study of Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone (Isa-KRd) versus Carfilzomib-Lenalidomide-Dexamethasone (KRd) in newly diagnosed multiple m | Not stated | 3 | - | - |
| NCT03104842 Trial register | Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone | running, but no longer enrolling | - | 2017-04-07 | - |
| NCT07082270 Trial register | Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma | withdrawn before enrolling anyone | - | 2025-07-24 | - |
| NCT05497804 Trial register | Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial | running, but no longer enrolling | - | 2022-08-11 | - |
| NCT04263480 Trial register | Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia | running, but no longer enrolling | - | 2020-02-10 | - |
| NCT03934684 Trial register | Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma | completed | - | 2019-05-02 | Posted |
| NCT05060627 Trial register | Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide | running, but no longer enrolling | - | 2021-09-29 | - |
| 2024-519353-11-00 Trial register | Iceland Screens Treats or Prevents Multiple Myeloma (iStopMM): A nationwide phase 2 trial of patients with smoldering and active multiple myeloma (MM) | Not stated | 2 | - | - |
| NCT01816971 Trial register | Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma | completed | - | 2013-03-22 | Posted |
| 2025-521090-14-00 Trial register | A Phase 2, single arm Multicenter, Study testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants with Relapsed or Refractory Multiple Myelo | Not stated | 2 | - | - |
| 2024-513396-41-00 Trial register | CARFILZOMIB - LENALIDOMIDE - DEXAMETHASONE (KRd) versus LENALIDOMIDE - DEXAMETHASONE (Rd) IN NEWLY DIAGNOSED MYELOMA PATIENTS NOT ELIGIBLE FOR AUTOLOGOUS STEM C | Not stated | 3 | - | - |
| NCT02203643 Trial register | Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT | completed | - | 2014-07-30 | - |
| NCT03500445 Trial register | Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma | running, but no longer enrolling | - | 2018-04-18 | - |
| NCT05572515 Trial register | A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed | running, but no longer enrolling | - | 2022-10-07 | - |
| 2024-519504-27-00 Trial register | An Open-label, Randomized Phase 3 Study of Linvoseltamab Monotherapy and Linvoseltamab plus Carfilzomib versus Standard of Care Combination Regimens in Patients | Not stated | 3 | - | - |
| NCT02405364 Trial register | Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone Induction | completed | - | 2015-04-01 | - |
| NCT05017545 Trial register | Carfilzomib and Belatacept for Desensitization | running, but no longer enrolling | - | 2021-08-24 | - |
| NCT02302495 Trial register | Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma | completed | - | 2014-11-27 | - |
| NCT01813227 Trial register | A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531 | completed | - | 2013-03-18 | Posted |
| NCT06249282 Trial register | Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer | currently recruiting participants | - | 2024-02-08 | - |
| NCT06536413 Trial register | ATRA and Carfilzomib in Plasma Cell Myeloma Patients | currently recruiting participants | - | 2024-08-05 | - |
| NCT04268498 Trial register | A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma | running, but no longer enrolling | - | 2020-02-13 | - |
| NCT02773030 Trial register | A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma | running, but no longer enrolling | - | 2016-05-16 | Posted |
| NCT05896228 Trial register | Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma | currently recruiting participants | - | 2023-06-09 | - |
| NCT01572480 Trial register | Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma | completed | - | 2012-04-06 | Posted |
| NCT03361306 Trial register | LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma | completed | - | 2017-12-04 | Posted |
| NCT02659293 Trial register | Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma | running, but no longer enrolling | - | 2016-01-20 | - |
| NCT03729804 Trial register | Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma ( | running, but no longer enrolling | - | 2018-11-05 | - |
| NCT04827563 Trial register | Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib | terminated before completion | - | 2021-04-01 | - |
| 2024-511929-60-00 Trial register | Efficacy and safety of Carfilzomib in combination with Ibrutinib vs. Ibrutinib alone in Waldenström’s Macroglobulinemia (CZAR-1) | Not stated | 2 | - | - |
| NCT04764942 Trial register | Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial | running, but no longer enrolling | - | 2021-02-21 | - |
| NCT06356571 Trial register | A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Mu | currently recruiting participants | - | 2024-04-10 | - |
| 2024-515770-27-00 Trial register | A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of Etentamig Monotherapy or Etentamig Combinations in Subjects with Multiple Myeloma | Not stated | 1/2 | - | - |
| 2023-507871-23-00 Trial register | C1071032 - MAGNETISMM-32 A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMALIDOMIDE, BORTEZOMIB | Not stated | 3 | - | - |
| NCT03031730 Trial register | Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma | terminated before completion | - | 2017-01-26 | Posted |
| NCT03275285 Trial register | Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma | completed | - | 2017-09-07 | Posted |
| NCT05556616 Trial register | A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma | terminated before completion | - | 2022-09-27 | Posted |
| NCT02969837 Trial register | Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma | completed | - | 2016-11-21 | Posted |
| NCT07348393 Trial register | A Phase 2, Single Arm Multicenter, Study Testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants With Relapsed or Refractory Multiple Myelom | not yet recruiting participants | - | 2026-01-16 | - |
| NCT05013190 Trial register | A Study of NINLARO® in Chinese Adults With Multiple Myeloma | running, but no longer enrolling | - | 2021-08-18 | - |
| NCT05675319 Trial register | Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Ther | terminated before completion | - | 2023-01-09 | - |
| NCT05704049 Trial register | A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple | running, but no longer enrolling | - | 2023-01-30 | - |
| NCT01665794 Trial register | Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | - | 2012-08-15 | - |
| NCT02970747 Trial register | Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone or in Combination With Darzalex® and Dexamethasone | completed | - | 2016-11-22 | - |
| NCT02937571 Trial register | High Dose Carfilzomib for Newly Diagnosed Myeloma | completed | - | 2016-10-18 | Posted |
| NCT02199665 Trial register | Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | - | 2014-07-24 | - |
| 2024-516908-42-00 Trial register | A phase II multicenter study of carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy, followed by high-dose therapy with melphalan and autolog | Not stated | 2 | - | - |
| NCT02512926 Trial register | Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children | completed | - | 2015-07-31 | - |
| 2024-516630-35-01 Trial register | A MULTICENTER, RANDOMIZED, OPEN LABEL PHASE II STUDY OF CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (CCyd) as pre transplant INDUCTION and post transplant c | Not stated | 2 | - | - |
| NCT01863550 Trial register | Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma | running, but no longer enrolling | - | 2013-05-29 | - |
| NCT04191616 Trial register | Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet | completed | - | 2019-12-10 | Posted |
| NCT06793475 Trial register | Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease | currently recruiting participants | - | 2025-01-27 | - |
| NCT03314636 Trial register | Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment. | running, but no longer enrolling | - | 2017-10-19 | - |
| NCT02899052 Trial register | Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM) | running, but no longer enrolling | - | 2016-09-14 | - |
| NCT04813653 Trial register | Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myelom | completed | - | 2021-03-24 | - |
| NCT07051850 Trial register | Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies | currently recruiting participants | - | 2025-06-09 | - |
| NCT06409702 Trial register | Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection | currently recruiting participants | - | 2024-05-10 | - |
| NCT02303821 Trial register | Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia | completed | - | 2014-12-01 | Posted |
| 2024-516670-29-00 Trial register | ISKPD-IFM2018-03-Multicenter Open label Phase 2 study of Isatuximab plus Pomalidomide and Dexamethasone with Carfilzomib in Relapsed or Refractory Multiple Myel | Not stated | 2 | - | - |
| NCT03432741 Trial register | Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV | terminated before completion | - | 2018-02-14 | - |
| NCT03158688 Trial register | Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma. | completed | - | 2017-05-18 | Posted |
| NCT04892446 Trial register | Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma | terminated before completion | - | 2021-05-19 | Posted |
| NCT03756896 Trial register | Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma | running, but no longer enrolling | - | 2018-11-28 | - |
| NCT03412565 Trial register | A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens | completed | - | 2018-01-26 | Posted |
| NCT01998971 Trial register | A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma | completed | - | 2013-12-03 | - |
| NCT06140966 Trial register | Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-ri | currently recruiting participants | - | 2023-11-21 | - |
| NCT06913192 Trial register | Efficacy of Sequential BCMA CAR-T Cell Therapy Following Autologous Hematopoietic Stem Cell Transplantation in Transplant-eligible Newly Diagnosed Multiple Myel | not yet recruiting participants | - | 2025-03-29 | - |
| 2024-518473-34-00 Trial register | A Randomized, Open-label Phase 3 Study of Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patien | Not stated | 3 | - | - |
| NCT03871829 Trial register | Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab | terminated before completion | - | 2019-03-12 | Posted |
| NCT04513639 Trial register | The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study | currently recruiting participants | - | 2020-08-14 | - |
| NCT06879379 Trial register | KPD Consolidation After ASCT in NDMM Patients | currently recruiting participants | - | 2025-03-17 | - |
| NCT06158412 Trial register | All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma | currently recruiting participants | - | 2023-11-22 | - |
| NCT06796517 Trial register | Immunotherapy in Lymphoma | currently recruiting participants | - | 2025-01-19 | - |
| NCT03773107 Trial register | LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma | completed | - | 2018-12-12 | Posted |
| NCT01903811 Trial register | S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma | completed | - | 2013-07-19 | Posted |
| NCT06561854 Trial register | Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone | currently recruiting participants | - | 2024-08-07 | - |
| NCT02315716 Trial register | Carfilzomib/Cyclophosphamide/Dexamethasone with Maintenance Carfilzomib in Multiple Myeloma | running, but no longer enrolling | - | 2014-12-12 | - |
| NCT03989414 Trial register | A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in | running, but no longer enrolling | - | 2019-06-18 | - |
| NCT01857115 Trial register | Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (wCCyd) | completed | - | 2013-05-20 | - |
| NCT06682156 Trial register | Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients | currently recruiting participants | - | 2024-11-12 | - |
| NCT04934475 Trial register | MInimal Residual Disease Adapted Strategy | running, but no longer enrolling | - | 2021-05-11 | - |
| 2024-514702-31-00 Trial register | Daratumumab in combination with Carfilzomib, Pomalidomide and Dexamethasone (DCPD) in patients with multiple myeloma induced acute renal failure - "Time is Kidn | Not stated | 2 | - | - |
| 2024-517006-28-00 Trial register | An open label, multicenter, phase I/II study of belantamab mafodotin in combination with Kd for the treatment of relapsed myeloma patients, refractory to lenali | Not stated | 1/2 | - | - |
| NCT02002598 Trial register | Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma | terminated before completion | - | 2013-12-06 | Posted |
| 2024-511334-12-00 Trial register | HOVON 147 MM: Carfilzomib, Lenalidomide and Dexamethasone versus Lenalidomide and Dexamethasone in High- Risk Smoldering Multiple Myeloma: A Randomized Phase 2 | Not stated | 2 | - | - |
| NCT03530683 Trial register | A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participa | terminated before completion | - | 2018-05-21 | - |
| NCT06568952 Trial register | Right Ventricular Function in Patients Taking Carfilzomib | completed | - | 2024-08-23 | - |
| NCT03859427 Trial register | A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple My | completed | - | 2019-03-01 | Posted |
| NCT02148913 Trial register | Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma | completed | - | 2014-05-28 | Posted |
| NCT06232707 Trial register | A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | withdrawn before enrolling anyone | - | 2024-01-31 | - |
| NCT02073097 Trial register | Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma | completed | - | 2014-02-27 | Posted |
| NCT02101944 Trial register | Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | - | 2014-04-02 | - |
| NCT01941316 Trial register | Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients | completed | - | 2013-09-13 | Posted |
| NCT02341014 Trial register | Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas | completed | - | 2015-01-19 | Posted |
| NCT02891811 Trial register | Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy | completed | - | 2016-09-08 | - |
| NCT02056756 Trial register | Carfilzomib In Combination With Bendamustine And Dexamethasone In Refractory Or Relapsed Multiple Myeloma | completed | - | 2014-02-06 | - |
| NCT06203145 Trial register | A Clinical Study on the Whole-course Management (BCD-KPD-AutoHSCT) Scheme for Patients With RIMM | last verified some time ago; the register no longer confirms its status | - | 2023-12-21 | - |
| NCT03289299 Trial register | Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant | running, but no longer enrolling | - | 2017-09-20 | - |
| NCT02318784 Trial register | Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers | completed | - | 2014-12-17 | Posted |
| NCT03224507 Trial register | Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma | completed | - | 2017-07-10 | Posted |
| NCT02188368 Trial register | Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients | terminated before completion | - | 2014-07-07 | - |
| NCT02294357 Trial register | Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib | terminated before completion | - | 2014-11-19 | - |
| NCT03673826 Trial register | Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM | running, but no longer enrolling | - | 2018-09-17 | - |
| NCT02206425 Trial register | Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients | completed | - | 2014-08-01 | - |
| NCT03605719 Trial register | Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma | completed | - | 2018-07-30 | - |
| NCT01301807 Trial register | Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma | completed | - | 2011-02-23 | - |
| NCT03155100 Trial register | Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-3 Prior Treatment Lines | completed | - | 2017-05-16 | - |
| NCT01336920 Trial register | Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma | completed | - | 2011-04-18 | - |
| NCT01346787 Trial register | Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients | completed | - | 2011-05-03 | - |
| NCT03201250 Trial register | Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma | terminated before completion | - | 2017-06-28 | Posted |
| NCT02597062 Trial register | High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma | completed | - | 2015-11-04 | Posted |
| NCT02185820 Trial register | Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD) | completed | - | 2014-07-10 | - |
| NCT02204241 Trial register | Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients | completed | - | 2014-07-30 | - |
| NCT05909826 Trial register | Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM | not yet recruiting participants | - | 2023-06-18 | - |
| NCT03948035 Trial register | Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM | running, but no longer enrolling | - | 2019-05-13 | - |
| NCT04895410 Trial register | Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Or | terminated before completion | - | 2021-05-20 | - |
| NCT02336815 Trial register | Selinexor Treatment of Refractory Myeloma | completed | - | 2015-01-08 | Posted |
| NCT02628704 Trial register | Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma | withdrawn before enrolling anyone | - | 2015-12-11 | - |
| NCT04287855 Trial register | Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma | last verified some time ago; the register no longer confirms its status | - | 2020-02-27 | - |
| NCT03091127 Trial register | Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe | completed | - | 2017-03-27 | - |
| NCT01568866 Trial register | Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients | completed | - | 2012-04-02 | Posted |
| NCT03416374 Trial register | A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple | completed | - | 2018-01-31 | Posted |
| NCT01677858 Trial register | A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma | completed | - | 2012-09-03 | Posted |
| NCT02412878 Trial register | Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma | completed | - | 2015-04-09 | Posted |
| NCT01080391 Trial register | Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma | completed | - | 2010-03-04 | Posted |
| NCT03891355 Trial register | Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL | last verified some time ago; the register no longer confirms its status | - | 2019-03-27 | - |
| NCT03742297 Trial register | Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years | running, but no longer enrolling | - | 2018-11-15 | - |
| NCT02415413 Trial register | Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma | running, but no longer enrolling | - | 2015-04-14 | - |
| NCT03336073 Trial register | Carfilzomib, Cyclophosphamide, Dexamethasone in Multiple Myeloma | last verified some time ago; the register no longer confirms its status | - | 2017-11-08 | - |
| NCT05509374 Trial register | Phase II Study of Carfilzomib, Pomalidomide, and Dexamethasone for Myeloma Patients Who Had Relapsed or Progressed After Carfilzomib, Lenalidomide, and Dexameth | last verified some time ago; the register no longer confirms its status | - | 2022-08-22 | - |
| NCT05497102 Trial register | Carfilzomib, Lenalidomide, and Dexamethasone Re-induction Followed by the 2nd ASCT in Multiple Myeloma Patients Relapsed After the 1st ASCT | last verified some time ago; the register no longer confirms its status | - | 2022-08-11 | - |
| NCT05495620 Trial register | Long-term KRd in Relapsed and/or Refractory Multiple Myeloma | last verified some time ago; the register no longer confirms its status | - | 2022-08-10 | - |
| NCT01464034 Trial register | A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | terminated before completion | - | 2011-11-03 | - |
| NCT02551718 Trial register | High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia | completed | - | 2015-08-25 | Posted |
| NCT03029234 Trial register | Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma | completed | - | 2017-01-24 | Posted |
| NCT03141203 Trial register | Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma Patients | completed | - | 2017-05-05 | - |
| NCT03256045 Trial register | Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | terminated before completion | - | 2017-08-21 | Posted |
| NCT02474927 Trial register | Combination Therapy With Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation | completed | - | 2015-06-18 | Posted |
| NCT03104270 Trial register | Combination Study for High Risk Multiple Myeloma Patients | terminated before completion | - | 2017-04-07 | - |
| NCT04163107 Trial register | Combined Carfilzomib and Hydroxychloroquine in Patients With Relapsed/Refractory Multiple Myeloma | completed | - | 2019-11-14 | - |
| NCT02293109 Trial register | Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma | completed | - | 2014-11-18 | - |
| NCT04811508 Trial register | Retrospective Study to Describe Carfilzomib Use on Patients With Relapsed Multiple Myeloma in France in the Context of Carfilzomib Nominative Expanded Access an | completed | - | 2021-03-23 | - |
| NCT03375567 Trial register | Global Response Assessment by Advanced Imaging and Myeloma Lesion Biopsies During Induction Therapy of Multiple Myeloma With Carfilzomib Lenalidomide Dexamethas | completed | - | 2017-12-18 | - |
| NCT01496118 Trial register | Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma | completed | - | 2011-12-21 | Posted |
| NCT04065789 Trial register | Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients | completed | - | 2019-08-22 | - |
| NCT05184595 Trial register | Cost-Utility Analysis of Home-based Versus Hospital-based Chemotherapy in Multiple Myeloma: Case of Carfilzomib | last verified some time ago; the register no longer confirms its status | - | 2022-01-11 | - |
| NCT02145403 Trial register | Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies | completed | - | 2014-05-22 | Posted |
| NCT01962792 Trial register | Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma | completed | - | 2013-10-14 | Posted |
| NCT02867618 Trial register | Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma | terminated before completion | - | 2016-08-16 | Posted |
| NCT04288765 Trial register | Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone as First Line Treatment in Multiple Myeloma | withdrawn before enrolling anyone | - | 2020-02-28 | - |
| NCT02128230 Trial register | UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission | terminated before completion | - | 2014-04-29 | Posted |
| NCT03543579 Trial register | Cardiovascular Complications of Carfilzomib Treatment | last verified some time ago; the register no longer confirms its status | - | 2018-06-01 | - |
| NCT03606577 Trial register | An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma | running, but no longer enrolling | - | 2018-07-31 | - |
| NCT03795597 Trial register | Busulfan, Melphalan, Escalating Carfilzomib Conditioning Auto Stem Cell Transplantation for Multiple Myeloma (MM) | last verified some time ago; the register no longer confirms its status | - | 2019-01-08 | - |
| NCT02187133 Trial register | Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | completed | - | 2014-07-10 | - |
| NCT02545907 Trial register | A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis | completed | - | 2015-09-10 | Posted |
| NCT02036502 Trial register | A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023) | terminated before completion | - | 2014-01-15 | Posted |
| NCT01402284 Trial register | Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients | completed | - | 2011-07-26 | Posted |
| NCT02095834 Trial register | Carfilzomib, Bendamustine Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | - | 2014-03-26 | - |
| NCT03512353 Trial register | A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers | terminated before completion | - | 2018-04-30 | Posted |
| NCT04621955 Trial register | Observational Study of Home Administration of Carfilzomib | withdrawn before enrolling anyone | - | 2020-11-09 | - |
| NCT02335983 Trial register | Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma | completed | - | 2015-01-12 | Posted |
| NCT02788201 Trial register | Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma | completed | - | 2016-05-28 | Posted |
| NCT02217163 Trial register | Carfilzomib, Cyclophosphamide, Dexamethasone in Transplant Eligible Newly Diagnosed High-risk Multiple Myeloma | completed | - | 2014-08-15 | - |
| NCT01989325 Trial register | A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple Myeloma | completed | - | 2013-11-21 | - |
| NCT02178579 Trial register | Prospective Observation of Cardiac Safety With Proteasome Inhibition | completed | - | 2014-06-26 | - |
| NCT01842308 Trial register | Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma | completed | - | 2013-04-29 | Posted |
| NCT02442648 Trial register | B-Cell Targeted Carfilzomib Desensitization | last verified some time ago; the register no longer confirms its status | - | 2015-05-13 | - |
| NCT04407858 Trial register | Cardiovascular Complications of Carfilzomib | last verified some time ago; the register no longer confirms its status | - | 2020-05-29 | - |
| NCT02265510 Trial register | An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies | terminated before completion | - | 2014-10-16 | Posted |
| NCT01775930 Trial register | Carfilzomib in Refractory Renal Cell Carcinoma (RCC) | completed | - | 2013-01-25 | Posted |
| NCT03269552 Trial register | Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma | terminated before completion | - | 2017-08-31 | Posted |
| NCT01729104 Trial register | Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma | terminated before completion | - | 2012-11-20 | - |
| NCT01738594 Trial register | Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma | terminated before completion | - | 2012-11-30 | Posted |
| NCT01818752 Trial register | Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma | completed | - | 2013-03-26 | Posted |
| NCT03815279 Trial register | A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM) | enrolling by invitation only | - | 2019-01-24 | - |
| NCT00932698 Trial register | Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma | completed | - | 2009-07-01 | Posted |
| NCT01372540 Trial register | Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia | completed | - | 2011-06-14 | - |
| NCT02811822 Trial register | A Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care for the Treatment of Multiple Myeloma | completed | - | 2016-06-20 | - |
| NCT04004338 Trial register | Carfilzomib in Combination for the Treatment of RR MM | last verified some time ago; the register no longer confirms its status | - | 2019-07-02 | - |
| NCT03805178 Trial register | Lung Transplant Plasmapheresis/Belatacept/Carfilzomib for Antibody Mediated Rejection and Desensitization | withdrawn before enrolling anyone | - | 2019-01-15 | - |
| NCT02042950 Trial register | A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma | terminated before completion | - | 2014-01-23 | Posted |
| NCT01246063 Trial register | Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | - | 2010-11-23 | Posted |
| NCT02269085 Trial register | Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma | terminated before completion | - | 2014-10-20 | - |
| NCT02491359 Trial register | Carfilzomib in Treating Patients With Chronic Graft-Versus-Host Disease | completed | - | 2015-07-08 | Posted |
| NCT01549431 Trial register | Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma | completed | - | 2012-03-09 | - |
| NCT02047253 Trial register | Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment | completed | - | 2014-01-28 | Posted |
| NCT01470196 Trial register | Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia | completed | - | 2011-11-11 | Posted |
| NCT02572492 Trial register | Study of Carfilzomib in Multiple Myeloma Relapsed After High-dose Melphalan With Autologous Stem Cell Support | last verified some time ago; the register no longer confirms its status | - | 2015-10-09 | - |
| NCT01690143 Trial register | Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation | completed | - | 2012-09-21 | Posted |
| NCT01554852 Trial register | Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients | last verified some time ago; the register no longer confirms its status | - | 2012-03-15 | - |
| NCT00884312 Trial register | A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols | completed | - | 2009-04-20 | Posted |
| NCT01365559 Trial register | Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments | completed | - | 2011-06-03 | - |
| NCT01792102 Trial register | Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple Myeloma | last verified some time ago; the register no longer confirms its status | - | 2013-02-15 | - |
| NCT02142530 Trial register | Carfilzomib Plus Belinostat in Relapsed/Refractory NHL | completed | - | 2014-05-20 | - |
| NCT00963820 Trial register | Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma | completed | - | 2009-08-20 | Posted |
| NCT01057225 Trial register | Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma | completed | - | 2010-01-27 | Posted |
| NCT01969565 Trial register | Study of Carfilzomib in Combination w/Dexamethasone in Patients w/Newly Diagnosed Multiple Myeloma | terminated before completion | - | 2013-10-25 | Posted |
| NCT03140943 Trial register | Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma | last verified some time ago; the register no longer confirms its status | - | 2017-05-04 | - |
| NCT01660750 Trial register | A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma | completed | - | 2012-08-09 | - |
| NCT01789242 Trial register | A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis | completed | - | 2013-02-12 | - |
| NCT01926665 Trial register | Carfilzomib Consolidation Therapy After Autologous Stem Cell Transplantation (ASCT) for Mantle Cell Lymphoma (MCL), T-cell Lymphoma (TCL), and Diffuse Large B-C | completed | - | 2013-08-21 | - |
| NCT00511238 Trial register | Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma | completed | - | 2007-08-03 | Posted |
| NCT01987232 Trial register | Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer | completed | - | 2013-11-19 | Posted |
| NCT00531284 Trial register | Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma | completed | - | 2007-09-18 | Posted |
| NCT01775553 Trial register | Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib | completed | - | 2013-01-25 | Posted |
| NCT00603447 Trial register | Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma | completed | - | 2008-01-29 | Posted |
| NCT01980589 Trial register | A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects | completed | - | 2013-11-11 | Posted |
| NCT00150462 Trial register | Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies | completed | - | 2005-09-08 | Posted |
| NCT00530816 Trial register | Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma | completed | - | 2007-09-18 | Posted |
| NCT00721734 Trial register | Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function | completed | - | 2008-07-24 | Posted |
| NCT01302392 Trial register | A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma | completed | - | 2011-02-24 | Posted |
| NCT01410500 Trial register | Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease | approved for marketing | - | 2011-08-05 | - |
| NCT01949532 Trial register | Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease | completed | - | 2013-09-24 | Posted |
| NCT01949545 Trial register | Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment | completed | - | 2013-09-24 | Posted |
| NCT02802163 Trial register | Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat | withdrawn before enrolling anyone | - | 2016-06-16 | - |
| NCT01351623 Trial register | Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma | completed | - | 2011-05-11 | Posted |
| NCT02257476 Trial register | Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors | completed | - | 2014-10-06 | - |
| NCT01029054 Trial register | Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma | completed | - | 2009-12-09 | Posted |
| NCT01812720 Trial register | Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant | withdrawn before enrolling anyone | - | 2013-03-18 | - |
| NCT02756663 Trial register | Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma | withdrawn before enrolling anyone | - | 2016-04-29 | - |
| NCT02020941 Trial register | Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy | terminated before completion | - | 2013-12-25 | Posted |
| NCT01137747 Trial register | Carfilzomib in Patients With Relapsed Acute Myeloid or Acute Lymphoblastic Leukemia | completed | - | 2010-06-04 | - |
| NCT01658904 Trial register | Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma | terminated before completion | - | 2012-08-07 | Posted |
| NCT01212380 Trial register | Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL) | completed | - | 2010-09-30 | - |
| NCT01204164 Trial register | Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies | completed | - | 2010-09-17 | - |
| NCT02235740 Trial register | A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to I | terminated before completion | - | 2014-09-10 | - |
| NCT01276717 Trial register | Study of Carfilzomib and Vorinostat for Relapsed or Refractory Lymphoma | completed | - | 2011-01-13 | - |
| NCT01991301 Trial register | Carfilzomib for the Prevention of Graft Versus Host Disease | last verified some time ago; the register no longer confirms its status | - | 2013-11-25 | - |
| NCT00999414 Trial register | UARK 2009-32 Compassionate Use Study of Carfilzomib | no longer available | - | 2009-10-21 | - |
| NCT01537861 Trial register | Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma | terminated before completion | - | 2012-02-23 | - |
| NCT02114502 Trial register | Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma | withdrawn before enrolling anyone | - | 2014-04-15 | - |
Source: ClinicalTrials.gov and EU CTIS, read 2026-10-03. Not medical advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.